Fibromyalgia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Fibromyalgia Therapeutics - Pipeline Assessment and Market
Forecasts to 2018
Published on November 2011

Report Summary

Fibromyalgia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Fibromyalgia Therapeutics - Pipeline Assessment and
Market Forecasts to 2018'. The report is an essential source of information and analysis on the global FM market. The report
identifies the key trends shaping and driving the global FM market. The report also provides insights on the prevalent competitive
landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most
importantly, the report provides valuable insights on the pipeline products within the global FM sector. This report is built using data
and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of
industry experts.

The global market for Fibromyalgia (FM) was valued at $1.7 billion in 2010 and is expected to grow at a Compound Annual Growth
Rate (CAGR) of 4.3% to reach $2.4 billion by 2018. The restricted growth in the market is due to the unavailability of approved drugs
in the EU and Japan market, expected patent expiry of Cymbalta (2013) and Lyrica (2018) and lack of newer therapies in late stage
FM therapeutics pipeline. Currently, FDA (Food and Drug Administration) has approved three drugs for the treatment of FM. Lyrica
(pregabalin) was the first drug approved in June 2007 followed by Cymbalta (duloxetine) in June 2008 and Savella (milnacipran) in
January 2009. Marketing authorization of these drugs has been rejected by EMEA (European Medical Agency) due low effectiveness
and high adverse reactions associated with the drugs. Cymbalta was the first drug to be rejected by EMEA in 2008, followed by Lyrica
in 2009 and Savella in 2010. However, increasing prevalence and diagnosis is expected to drive the future FM therapeutics market.

Note: This is a on-demand report and will be delivered within 3 business days of the purchase (excluding weekends).

Scope

The report provides information on the key drivers and challenges of the FM market. Its scope includes -
- Annualized global FM market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends.
Pipeline candidates fall under major therapeutic classes such as therapies based on SSRI and GABA agonist calcium channel
blocker, sodium channel blocker, nonrepinephrine reuptake inhibitor, NMDA antagonist.
- Analysis of the current and future competition in the global FM market. Key market players covered are the Pfizer, Jazz
Pharmaceuticals and UCB.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a
qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the FM
therapeutics market.

Reasons to buy

Fibromyalgia Therapeutics - Pipeline Assessment and Market Forecasts to 2018 (From Slideshare) Page 1/8


The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by
identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global FM market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to
impact the global FM market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of
various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive
advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities
for consolidations, investments and strategic partnerships.
- What's the next big thing in the global FM market landscape' ' Identify, understand and capitalize.

Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 7
2 Fibromyalgia Therapeutics: Executive Summary 9
2.1 The Fibromyalgia (FM) Therapeutics Market is Forecast to Show Slow Growth Until 2018 9
2.2 Weak Market Served by Three FDA Approved Products Targeting Symptomatic Relief 10
2.3 Fibromyalgia Therapeutics Market has High Unmet Need 10
2.4 Weak Pipeline with Lack of Promising Molecules 11
2.5 Implications for the Future Market 12
3 Fibromyalgia Therapeutics: Introduction 13
3.1 Overview 13
3.2 Epidemiology 13
3.2.1 Prevalence 13
3.2.2 Co-Morbidities 15
3.2.3 Quality of Life: 15
3.2.4 Economic Burden: 16
3.3 Etiology and Pathophysiology 16
3.4 Symptoms 17
3.5 Diagnosis 18
3.6 Treatment and Management Pattern 20
3.7 Referral Pathway 22
3.8 GlobalData Pipeline Report Guidance 22
4 Fibromyalgia Therapeutics: Market Characterization 24
4.1 Fibromyalgia Therapeutics Market Size (2005 - 2010) - Global 24
4.2 Fibromyalgia Therapeutics Market Forecast (2010 - 2018) - Global 25
4.3 Fibromyalgia Therapeutics Market Size (2005 - 2010): The US 26
4.4 Fibromyalgia Therapeutics Market Forecast (2010-2018): The US 27
4.5 Fibromyalgia Therapeutics Market (2005 - 2010): France 28
4.6 Fibromyalgia Therapeutics Market Forecast (2010 - 2018): France 29



4.7 Fibromyalgia Therapeutics Market (2005 - 2010): Germany 30
4.8 Fibromyalgia Therapeutics Market Forecast (2010 - 2018): Germany 32
4.9 Fibromyalgia Therapeutics Market (2005 - 2010): Italy 33
4.10 Fibromyalgia Therapeutics Market Forecast (2010 - 2018): Italy 34
4.11 Fibromyalgia Therapeutics Market (2005 - 2010): Spain 35
4.12 Fibromyalgia Therapeutics Market Forecast (2010 - 2018): Spain 36
4.13 Fibromyalgia Therapeutics Market (2005 - 2010): The UK 37
4.14 Fibromyalgia Therapeutics Market Forecast (2010 - 2018): The UK 38
4.15 Fibromyalgia Therapeutics Market (2005 - 2010): Japan 39
4.16 Fibromyalgia Therapeutics Market Forecast (2010 - 2018): Japan 40
4.17 Drivers and Barriers for the Fibromyalgia Therapeutics Market 41
4.17.1 Drivers for the Fibromyalgia Therapeutics Market 41
4.17.2 Barriers for the Fibromyalgia Therapeutics Market 41
4.18 Opportunity and Unmet Need Analysis 42
4.19 Key Takeaway 43
5 Fibromyalgia Therapeutics: Competitive Assessment 44
5.1 Overview 44
5.2 Strategic Competitor Assessment 44
5.3 Product Profile for the Major Marketed Products in the Fibromyalgia Therapeutics Market 46
5.3.1 Lyrica (pregabalin) 46
5.3.2 Cymbalta (duloxetine) 48
5.3.3 Savella (milnacipran) 50
6 Fibromyalgia Therapeutics: Pipeline Assessment 52
6.1 Overview 52
6.2 Strategic Pipeline Assessment 52
6.3 Fibromyalgia Therapeutics Pipeline ' Pipeline by Phases of Development 52
6.3.1 Fibromyalgia Therapeutics ' Filed Pipeline 53
6.3.2 Fibromyalgia Therapeutics ' Phase III Pipeline 53
6.3.3 Fibromyalgia Therapeutics ' Phase II Pipeline 53
6.3.4 Fibromyalgia Therapeutics ' Phase I Pipeline 54
6.4 Fibromyalgia Therapeutics Market ' Pipeline by Mechanism of Action 54
6.5 Technology Trends Analytical Framework 55
6.6 Molecule Profile for Drugs under Late Stage Development 57
6.6.1 Lyrica (Pregabalin) 57
6.6.2 JZP-6 (sodium oxybate) 58
7 Fibromyalgia Therapeutics: Clinical Trials Mapping 61
7.1 Clinical Trials by Country (US, EU5 & Japan) 61
7.2 Clinical Trials by Phase 62
7.3 Clinical Trials by Trial Status 63
7.4 Prominent Sponsors 64
7.5 Key Companies Participating in Therapeutics Clinical Trials 65
8 Fibromyalgia Therapeutics: Stategic Assessment 67
8.1 Key Events Impacting on the Future Market 67
8.2 Fibromyalgia Therapeutics: Implications for Future Market Competition 67
9 Fibromyalgia Therapeutics: Future Players 70
9.1 Introduction 70
9.2 Company Profiles 71
9.2.1 Jazz Pharmaceuticals Inc. 71



9.2.2 Pfizer 72
9.2.3 UCB SA 73
9.2.4 Other Companies in the Fibromyalgia Therapeutics Market 74
10 Fibromyalgia Therapeutics: Licensing and Partnership Deals 76
11 Fibromyalgia Therapeutics: Appendix 78
11.1 Market Definitions 78
11.2 Abbreviations 78
11.3 Methodology 79
11.3.1 Coverage 79
11.3.2 Secondary Research 79
11.3.3 Forecasting 80
11.3.4 Primary Research 81
11.3.5 Expert Panel Validation 82
11.4 Contact Us 82
11.5 Disclaimer 82
11.6 Bibliography 83

List of Tables

Table 2: Fibromyalgia Therapeutics: Prevalence of FM in Top Seven Countries 15
Table 3: Fibromyalgia Therapeutics: Prevalence (%) of Co-Morbid Conditions Associated with FM 16
Table 4: Fibromyalgia Therapeutics: Quality of Life 17
Table 5: Fibromyalgia Therapeutics: NIH Spending 17
Table 6: Fibromyalgia Therapeutics: Prescribed Drugs 22
Table 8: Fibromyalgia Therapeutics Market, Global, Revenue($m), 2005-2010 26
Table 10: Fibromyalgia Therapeutics Market, Global, Forecast($m), 2010-2018 27
Table 12: Fibromyalgia Therapeutics Market, The US, Revenue($m), 2005-2010 28
Table 14: Fibromyalgia Therapeutics Market, The US, Forecast($m), 2010-2018 29
Table 16: Fibromyalgia Therapeutics Market, France, Revenue($m), 2005-2010 30
Table 18: Fibromyalgia Therapeutics Market, France, Forecast($m), 2010-2018 31
Table 20: Fibromyalgia Therapeutics Market, Germany, Revenue($m), 2005-2010 32
Table 22: Fibromyalgia Therapeutics Market, Germany, Forecast ($m), 2010-2018 33
Table 24: Fibromyalgia Therapeutics Market, Italy, Revenue ($m), 2005-2010 34
Table 26: Fibromyalgia Therapeutics Market, Italy, Forecast ($m), 2010-2018 35
Table 28: Fibromyalgia Therapeutics Market, Spain, Revenue ($m), 2005-2010 36
Table 30: Fibromyalgia Therapeutics Market, Spain, Forecast ($m), 2010-2018 37
Table 32: Fibromyalgia Therapeutics Market, UK, Revenue ($m), 2005-2010 38
Table 34: Fibromyalgia Therapeutics Market, UK, Forecast ($m), 2010-2018 39
Table 36: Fibromyalgia Therapeutics Market, Japan, Revenue ($m), 2005-2010 40
Table 38: Fibromyalgia Therapeutics Market, Japan, Forecast ($m), 2010-2018 41
Table 39: Fibromyalgia Therapeutics: Unmet Need Gap 43
Figure 41: Strategic Competitor Assessment of the Major Marketed Products for Fibromyalgia, 2011 46
Table 43: Fibromyalgia Therapeutics ' Filed Clinical Pipeline, 2011 54
Table 44: Fibromyalgia Therapeutics ' Phase III Clinical Pipeline, 2011 54
Table 45: Fibromyalgia Therapeutics ' Phase II Clinical Pipeline, 2011 54
Table 46: Fibromyalgia Therapeutics ' Phase l Pipeline, 2011 55
Table 50: Fibromyalgia Therapeutics ' Most Promising Drugs Under Development, 2011 58
Table 53: Fibromyalgia Therapeutics, Clinical Trials by Country,2011 63



Table 55: Fibromyalgia Therapeutics, Global, Clinical Trials by Phase of Development, 2011 64
Table 57: Fibromyalgia Therapeutics, Global, Clinical Trials by Trial Status, 2011 65
Table 26: Fibromyalgia Therapeutics, Global, Clinical Trials by Overall Sponsors, 2011 65
Table 27: Fibromyalgia Therapeutics, Global, Clinical Trials by Prominent Sponsors, 2011 66
Table 61: Fibromyalgia Therapeutics, Global, Clinical Trials by Top Companies, 2011 67
Table 29: Jazz Pharmaceuticals - CNS Pipeline Portfolio, 2011 72
Table 65: Pfizer Inc. - CNS Pipeline Portfolio, 2011 73
Table 66: Actelion Pharmaceuticals Ltd - CNS Pipeline Portfolio, 2011 74
Table 68: Other Companies in the Pipeline, 2011 75
Table 69: Licensing and Partnership Deals, 2006-2011 77

List of Figures

Figure 1: Fibromyalgia Therapeutics Market, Global, Revenues ($bn), 2005-2018 10
Figure 2: Opportunity and Unmet Need in the Fibromyalgia Therapeutics Market, 2010 12
Figure 1: Fibromyalgia Therapeutics: Prevalence With Age 14
Figure 3: Fibromyalgia Therapeutics: 18 Tender Points 20
Figure 4: Fibromyalgia Therapeutics: Referral Pathway 23
Figure 7: Fibromyalgia Therapeutics Market, Global, Revenue($m), 2005-2010 25
Figure 9: Fibromyalgia Therapeutics Market, Global, Forecast ($m), 2010-2018 26
Figure 11: Fibromyalgia Therapeutics Market, The US, Revenue($m), 2005-2010 28
Figure 13: Fibromyalgia Therapeutics Market, The US, Forecast($m), 2010-2018 29
Figure 15: Fibromyalgia Therapeutics Market, France, Revenue($m), 2005-2010 29
Figure 17: Fibromyalgia Therapeutics Market, France, Forecast($m), 2010-2018 31
Figure 19: Fibromyalgia Therapeutics Market, Germany, Revenue($m), 2005-2010 32
Figure 21: Fibromyalgia Therapeutics Market, Germany, Forecast ($m), 2010-2018 33
Figure 23: Fibromyalgia Therapeutics Market, Italy, Revenue ($m), 2005-2010 34
Figure 25: Fibromyalgia Therapeutics Market, Italy, Forecast ($m), 2010-2018 35
Figure 27: Fibromyalgia Therapeutics Market, Spain, Revenue ($m), 2005-2010 36
Figure 29: Fibromyalgia Therapeutics Market, Spain, Forecast ($m), 2010-2018 37
Figure 31: Fibromyalgia Therapeutics Market, UK, Revenue ($m), 2005-2010 38
Figure 33: Fibromyalgia Therapeutics Market, UK, Forecast ($m), 2010-2018 39
Figure 35: Fibromyalgia Therapeutics Market, Japan, Revenue ($m), 2005-2010 40
Figure 37: Fibromyalgia Therapeutics Market, Japan, Forecast ($m), 2010-2018 41
Figure 40: Opportunity and Unmet Need in the Fibromyalgia Therapeutics Market, 2010 43
Figure 4: Pain Reduction of Approved Products (Lyrica, Cymbalta and Savella) 47
Figure 5: Fibromyalgia Therapeutics: Molecular Structure of Lyrica 48
Figure 6: Fibromyalgia Therapeutics: Molecular Structure of Cymbalta 50
Figure 42: Fibromyalgia Therapeutics, Pipeline by Phase of Development, 2011 53
Figure 47: Fibromyalgia Therapeutics Market ' Pipeline by Mechanism of Action, 2011 55
Figure 48: Technology Trends Analytic Framework of the Fibromyalgia Therapeutics Pipeline, 2011 56
Figure 49: Technology Trends Analytic Framework of the Fibromyalgia Therapeutics Pipeline - Description, 2011 57
Figure 51: Fibromyalgia Therapeutics, Molecular Structure of Lyrica 59
Figure 52: Fibromyalgia Therapeutics - Clinical Trials by Country, 2011 62
Figure 54: Fibromyalgia Therapeutics, Global, Clinical Trials by Phase of Development, 2011 63
Figure 56: Fibromyalgia Therapeutics, Global, Clinical Trials by Trial Status, 2011 64
Figure 58: Fibromyalgia Therapeutics, Global, Clinical Trials by Overall Sponsors, 2011 65
Figure 59: Fibromyalgia Therapeutics, Global, Clinical Trials by Prominent Sponsors, 2011 66



Figure 60: Fibromyalgia Therapeutics, Global, Clinical Trials by Top Companies, 2011 67
Figure 62: Fibromyalgia Therapeutics Market, Drivers and Barriers, 2011 68
Figure 63: Implications for Future Market Competition in the Fibromyalgia Therapeutics Market, 2011 68
Figure 64: Fibromyalgia Therapeutics ' Clinical Pipeline by Company, 2011 70Jazz Pharmaceuticals Inc.
Pfizer
UCB SA


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.

Fibromyalgia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 3 500.00 Quantity: _____

Site License--USD 7 000.00 Quantity: _____

Corporate License--USD 10 500.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Fibromyalgia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Recomendados

Recomendados

Mais conteúdo relacionado

Mais de ReportLinker.com

Mais de ReportLinker.com (20)

Fibromyalgia Therapeutics - Pipeline Assessment and Market Forecasts to 2018